The translation of new discoveries into clinical use is challenging, expensive and time-consuming.
Basic researchers may not have the time, resources or expertise necessary to successfully navigate the complex, highly regulated drug development process. In addition, it can be difficult to fund the development and evaluation of novel treatments using traditional NIH research grants and resources.
The Center for Translational Medicine facilitates the development and implementation of novel, investigator-initiated treatment strategies.
The Center for Translational Medicine was established in 2007 to facilitate the development and implementation of novel, investigator-initiated treatment strategies by functioning as a service entity for AHC Community. Led by the Director Bruce Blazar, M.D., Co-Director John Wagner, M.D., and Scientific Director Robert Schumacher, Ph.D. the Center provides the infrastructure, expertise and resources necessary to translate innovative drugs and biological reagents into Phase 1 clinical trials.
The organization of the Center is highly focused on the integration of activities across the spectrum of product development, from translational research to clinical trial operations. The Center consists of an integrated continuum and matrix of resources and services, with availability of entry for therapeutic development or services at any point in the continuum from basic research and discovery to clinical trials.
Fully-staffed by personnel with necessary expertise, including personnel with academic and industry development experience, the Center works with academic and industry partners to coordinate translational development activities, compress development timelines, and effectively translate research into medicine.
By leveraging the expertise and capabilities of other University of Minnesota centers and institutes, such as Molecular and Cellular Therapeutics, the Institute for Therapeutics Discovery and Development, and the Center for Forecasting Drug Response, the Center for Translation Medicine supports and enhances the University's ability to form alliances with industry and major research organizations with a common goal to foster growth and innovation in the biotech and biopharmaceutical arena, and develop private sources of funding for leading research.